PARIS, Oct. 15, 2019 /PRNewswire/ -- Sanofi today
celebrates the inauguration of its new digital manufacturing
facility in Framingham,
Massachusetts, marking one of the world's first digital
facilities using intensified, continuous biologics production
technology.
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/8627651-sanofi-new-digital-manufacturing-facility/
The new facility features leading-edge technology that connects
the production process with research and development, paving the
way for improved commercialization of important new medicines for
patients.
This facility accelerates the recent transformation of Sanofi's
Industrial Affairs organization to focus on biologics-based
therapies, in line with the transformation of the company's R&D
pipeline. The ramping up of bio-pharmaceutical production
capacities is a key pillar to achieving Sanofi's ambition to
establish the gold standard in the bio-pharmaceutical industry.
Sanofi at the leading edge of biologics manufacturing
The facility's advanced paperless and data-driven manufacturing
technologies is expected to enable Sanofi to achieve higher levels
of productivity, agility, and flexibility, reducing the time it
takes for products to move from the development labs to the
manufacturing plant, and – most importantly – meeting the needs of
patients around the world.
"We have been investing for
some years to prepare for Sanofi's future. Our Framingham facility leads the way in
delivering the next generation of biologics manufacturing,
leveraging intensified, continuous processing in a fully integrated
digitally powered facility," said Philippe Luscan, Executive Vice President,
Global Industrial Affairs at Sanofi. "This opening demonstrates
we are at the leading edge of innovation and manufacturing
excellence, helping us to shape the future of both our
company and the industry."
The digital transformation of Sanofi's manufacturing network is
a key element of the company's goal to leverage better use of data
to optimize the company's manufacturing processes, increasing
efficiencies, improving the agility needed to respond to fast
changing patient needs, and speeding up the commercialization of
new medicines emerging from the R&D pipeline.
Framingham is the latest
biologics manufacturing facility amongst a number of pilots, which
are being accelerated across the Sanofi network. The innovations
established at this facility are being rapidly deployed and
standardized across the company. Framingham is the first "digitally born"
facility while similar digital transformations are introduced in
other legacy plants. Beyond Framingham, Sanofi intends to move forward
with digital transformation initiatives in Toronto (Canada), Suzano
(Brazil), Waterford
(Ireland), Sisteron (France), and Geel (Belgium).
Newest part of Sanofi's integrated biologics hub in
Framingham
The Framingham digital
bio-manufacturing facility is part of Sanofi's integrated,
cross-functional biologics hub in Framingham, Massachusetts. A critical global
hub for more than 30 years, the campus offers co-location of all
the infrastructure and activities required to speed the delivery of
innovative new therapies to patients, from early stage research and
process development through clinical and commercial manufacturing,
including the key enabling functions of quality control and
compliance, regulatory, engineering, supply chain, and learning and
development.
The co-location of these critical functions allows for seamless,
end-to-end product and process design and manufacturing and
provides leading-edge development opportunities for our employees'
competencies evolution.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
Media Relations
Contact
|
Investor Relations
Contact
|
Nicolas
Kressmann
|
George
Grofik
|
Tel.: +1 (732)
532-5318
|
Tel.: +33 (0)1 53 77
45 45
|
Nicolas.Kressmann@sanofi.com
|
ir@sanofi.com
|
Sanofi Forward-Looking Statements
This press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi's ability to benefit from external growth opportunities, to
complete related transactions and/or obtain regulatory clearances,
risks associated with intellectual property and any related pending
or future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic conditions, the impact of cost containment initiatives and
subsequent changes thereto, the average number of shares
outstanding as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those
listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F
for the year ended December 31, 2018.
Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information
or statements.
Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
View original
content:http://www.prnewswire.com/news-releases/sanofi-opens-its-first-digitally-enabled-continuous-manufacturing-facility-ushers-in-next-generation-of-biotech-manufacturing-300938236.html
SOURCE Sanofi